Clinical Trial Update: Imjudo & Imfinzi PMS

View source ↗

Summary

AstraZeneca-sponsored trial update notes ongoing recruitment for Imjudo (tremelimumab) plus Imfinzi (durvalumab) in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• IMJUDO (TREMELIMUMAB)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Status: RECRUITING